Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Global Industry Growth, Trends, and Forecast

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market is witnessing steady growth as awareness of this rare neurological disorder increases and treatment options continue to advance. According to Market Research Future, the global market was valued at USD 1,995.78 million in 2024 and is projected to reach USD 4,332.21 million by 2035, expanding at a CAGR of 7.3% during 2025–2035.

CIDP is a chronic autoimmune disorder that affects peripheral nerves and can cause progressive weakness, sensory disturbances, and impaired reflexes. Growing awareness among healthcare professionals and patients is supporting earlier diagnosis and increasing demand for effective therapies.

The market includes treatment options such as intravenous immunoglobulin, corticosteroids, plasmapheresis, immunotherapy, and physical therapy. Intravenous immunoglobulin remains an important treatment category because of its established clinical use. At the same time, innovative immunotherapies and targeted treatment approaches are creating new opportunities for pharmaceutical companies.

North America currently represents the leading regional market, supported by advanced healthcare infrastructure, strong research activity, and increasing diagnosis rates. Asia-Pacific is also emerging as an attractive growth region due to improving healthcare expenditure and awareness.

Overall, continued therapeutic innovation, personalized treatment approaches, patient-support programs, and rising investment in neurological research are expected to contribute significantly to the future expansion of the CIDP Market.

Read More
Lukoon https://lukoon.com